GGrantIndex
← Search

Pathology

$4,700P30FY2018CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Linked publications, trials & patents

Trial NCT07082270Trial NCT06202066Trial NCT05589844Trial NCT05338905Trial NCT05292521Trial NCT05231122Trial NCT04607291Trial NCT04533542Trial NCT04530812Trial NCT04526587Trial NCT04379518Trial NCT04358315Trial NCT04348747Trial NCT04298606Trial NCT04290962Trial NCT04269213Trial NCT04231539Trial NCT04207190Trial NCT04119830Trial NCT04110249Trial NCT04109924Trial NCT04093323Trial NCT04081389Trial NCT04073745Trial NCT04068649Trial NCT04067830Trial NCT04060446Trial NCT04032418Trial NCT04000581Trial NCT03965234Trial NCT03935347Trial NCT03899987Trial NCT03897270Trial NCT03895918Trial NCT03881735Trial NCT03880422Trial NCT03879694Trial NCT03865472Trial NCT03851081Trial NCT03793907Trial NCT03789877Trial NCT03751449Trial NCT03751436Trial NCT03736720Trial NCT03735589Trial NCT03735095Trial NCT03727789Trial NCT03727061Trial NCT03709550Trial NCT03691376Trial NCT03688945Trial NCT03685695Trial NCT03683147Trial NCT03680235Trial NCT03679585Trial NCT03679559Trial NCT03678350Trial NCT03630601Trial NCT03574792Trial NCT03457142Trial NCT03403634Trial NCT03384836Trial NCT03358719Trial NCT03348748Trial NCT03333486Trial NCT03297489Trial NCT03211416Trial NCT03206047Trial NCT03192397Trial NCT03090412Trial NCT03017131Trial NCT03011736Trial NCT02965976Trial NCT02955290Trial NCT02953457Trial NCT02947386Trial NCT02877641Trial NCT02857374Trial NCT02853318Trial NCT02833506Trial NCT02713373Trial NCT02650986Trial NCT02575885Trial NCT02575508Trial NCT02531906Trial NCT02474095Trial NCT02455557Trial NCT02452463Trial NCT02414724Trial NCT02399215Trial NCT02393755Trial NCT02334865Trial NCT02287727Trial NCT02227940Trial NCT02170389Trial NCT02166905Trial NCT02159950Trial NCT02119728Trial NCT02100254Trial NCT02072486

Abstract

The RPCI Pathology Resource Network (PRN) Shared Resource, directed by Dr. Carl Morrison (GN), provides specialized technologies, services, and expertise involving all aspects of biospecimens through 6 integrated facilities: 1) Tissue Procurement, 2) Pathology Core Facility, 3) Paraffin Archive, 4) Special Functions Laboratory, 5) Correlative Science Pathology Office (CSPO), and 6) Leukemia Bank. This centralization of all aspects of biospecimen research provides stability, reliability, cost-effectiveness, and quality control. The PRN utilizes a state-of-the-art Laboratory Information Management System (LIMS) to effectively manage tissue resources, and maintains the highest standards of quality control. The 34 full time faculty and staff (7 staff supported by CCSG funding) in the PRN provide key services, including: tissue procurement (MD leadership and 5 staff); state-of-the-art research histology (PhD leadership and 5 staff); archive curation and maintenance of formalin fixed paraffin-embedded (FFPE) tissue (2 staff); special laboratory functions including image scanning and analysis (1 PhD leader); tissue microarray (TMA) (1 staff); laser microdissection (1 staff); macromolecule processing (1 staff); spectral karyotyping (1 PhD leader, 1 staff; biospecimen clinical trials support (RN leadership and 5 staff); leukemia banking (MD leadership, 3 staff). Some staff have roles in more than one area. The (CSPO) is new since the last CCSG submission and provides an effective solution to the need for biospecimens and correlative science in clinical research. The PRN provides tissue biospecimens to more than 25 clinical trials on an annual basis and blood to almost all interventional studies. The PRN provides centralized equipment, including: immunohistochemistry autostainers, frozen tissue cryostats, freezer alarms and management systems, Aperio image scanning ScanScope, image analysis software, Arcturus and Leica tissue microdissection platforms. All of these are managed by the sophisticated multi-million dollar LIMS. Access to tissues at RPCI is determined by the various Disease Site Research Groups (DSRGs), but the overall guidelines are set by the Tissue Utilization Committee (TUC), in accordance with CCSG guidelines. The PRN provides services to multiple peer-review funded investigators and provides major contributions to The Cancer Genome Atlas [PI: Dr. Carl Morrison (GN)]. First priority for use is given to peer-review-funded RPCI CCSG members; second priority to non-peer-review- funded CCSG members; third priority to non-members and academic collaborators; and last priority to external users. During the reporting period, the PRN shared resource has served 85 members from 6 research programs, with 48% utilization by CCSG members with peer reviewed funding. The CCSG makes up 9% of the overall proposed budget.

View original record on NIH RePORTER →